All Trials

Intraperitoneal Paclitaxel With Standard Systemic NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis: Prospective Pilot Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with pancreatic ductal adenocarcinoma limited to the peritoneum (PCI ≤8, ECOG 0–1), including resectable/borderline/locally advanced disease and select patients with up to 4 months of prior FOLFIRINOX/NALIRIFOX without progression, receive intraperitoneal paclitaxel (microtubule stabilizer) on days 1 and 8 plus systemic NALIRIFOX (5-FU/leucovorin, liposomal irinotecan [topoisomerase I inhibitor], oxaliplatin) on day 1 of 14-day cycles up to 12 cycles. The trial evaluates safety and signals of efficacy, with goals of peritoneal disease control and potential conversion to surgery.

ClinicalTrials.gov ID: NCT07030283

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Newly diagnosed patients (>1 year) with widely metastatic Ewing sarcoma or metastatic CIC-rearranged sarcoma (no prior systemic therapy beyond an initial VDC cycle) receive an intensive, sequential 2-year regimen: VDC induction; IrIVA; cabozantinib during primary-site radiation (multi-kinase inhibitor of MET/VEGFR2/AXL); followed by topotecan/cyclophosphamide, high-dose ifosfamide, irinotecan/temozolomide, and prolonged alternating oral/IV maintenance (cyclophosphamide/etoposide and vincristine/liposomal doxorubicin). Aims to exploit non–cross-resistant “second strikes” and antiangiogenic targeting to suppress resistant clones; tumor tissue submission required.

ClinicalTrials.gov ID: NCT07194044

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adolescents and adults with advanced/metastatic soft tissue or bone sarcomas (expansion in unresectable recurrent/metastatic liposarcoma) receive cyclophosphamide conditioning followed by a single infusion of autologous TILs engineered to express a membrane-anchored, tumor-targeted IL‑12 payload to localize cytokine signaling in the TME. Aims to establish safety/dose and assess preliminary activity, with 4-month PFS as the key endpoint in liposarcoma.

ClinicalTrials.gov ID: NCT06474676

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic, HMB-45–positive clear cell sarcoma and measurable disease; HLA-A*02:01–positive patients receive tebentafusp, a gp100-directed TCR/anti-CD3 bispecific (ImmTAC) that redirects T cells, while HLA-A*02:01–negative patients get physician’s choice therapy. Key notes: weekly IV step-up dosing; common early toxicities include cytokine-mediated infusion reactions and rash.

ClinicalTrials.gov ID: NCT06942442

GPC-3 Chimeric Antigen Receptor T Cells FOR Recurrent GPC-3 Positive Glioblastoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults (≥18) with recurrent glioblastoma undergoing clinically indicated repeat resection whose tumor is GPC3-positive by IHC (≥25% with at least moderate intensity) and KPS ≥60. At surgery, patients receive a single intracavitary dose of autologous GPC3-targeted CAR T cells (GC33-derived) engineered to express IL-15 for enhanced expansion/persistence and incorporating an inducible caspase-9 (iCasp9) safety switch activatable with AP1903 if needed for toxicity control.

ClinicalTrials.gov ID: NCT06815432

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or locally recurrent unresectable triple-negative breast cancer (measurable disease; ECOG 0–2) receive low-dose oral cyclophosphamide plus axatilimab (CSF-1R–blocking antibody to modulate tumor-associated macrophages/myeloid suppression) combined with fixed standard-dose retifanlimab (PD-1 inhibitor). This single-arm dose-finding study focuses on safety/tolerability and identifying recommended doses for the cyclophosphamide/axatilimab additions.

ClinicalTrials.gov ID: NCT06959537

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced unresectable or metastatic/oligometastatic (≤5 sites) HPV+ or HPV− head and neck squamous cell carcinoma with measurable TROP2 IHC 2+/3+ disease and ECOG 0–1 receive lymphodepleting fludarabine/cyclophosphamide followed by allogeneic cord blood–derived TROP2-directed CAR-NK cells engineered to express IL-15 (to support NK persistence) and with TGFBR2 knockout (to resist TGF-β–mediated immunosuppression). Patients are treated in cohorts with CAR-NK therapy alone versus with preconditioning radiation/SBRT bridging when feasible (often leaving one measurable lesion unirradiated for response assessment).

ClinicalTrials.gov ID: NCT07101432

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For pediatric and young adult patients with relapsed/refractory non-CNS solid tumors confirmed to express glypican-3 (including hepatocellular carcinoma meeting Barcelona stage A–C and Child-Pugh <7), this study tests autologous GPC3-targeted CAR T cells “armored” with IL-15 and IL-21 to enhance expansion/persistence. Patients receive cyclophosphamide/fludarabine lymphodepletion followed by a single IV infusion of SC-CAR.GPC3xIL15.21 with dose escalation, with an inducible caspase-9 safety switch that can be activated using rimiducid for severe toxicity.

ClinicalTrials.gov ID: NCT07148050

A Phase I/II Study of Tebentafusp-tebn in Combination With Liver-Directed Therapies for the Treatment of Metastatic Uveal Melanoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling HLA-A*02:01–positive adults with metastatic uveal melanoma involving the liver (≥1 measurable liver lesion), ECOG 0–1; Part 1 focuses on low–moderate hepatic burden and no prior systemic therapy in the metastatic setting, while Part 2 includes bulky liver-dominant disease (largest lesion >5 cm and/or ≥50% liver involvement) and allows up to 2 prior systemic/liver-directed lines (excluding prior tebentafusp and prior chemoembolization). Patients receive weekly step-up tebentafusp-tebn (gp100/HLA-A*02:01–directed ImmTAC that redirects T cells via anti-CD3) alone or combined with hepatic immunoembolization plus GM-CSF (randomized vs tebentafusp alone in Part 1B), or sequential BCNU (carmustine) transarterial chemoembolization followed by tebentafusp in bulky disease (Part 2).

ClinicalTrials.gov ID: NCT06626516

Phase 2 Sequential Treatment With Melphalan/HDS Via Percutaneous Hepatic Perfusion Followed by Tebentafusp in the Treatment of Metastatic Uveal Melanoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with ECOG 0–1, HLA-A*02:01–positive metastatic uveal melanoma with liver-dominant disease (≤50% liver replacement) and at least one measurable hepatic lesion, with significant extrahepatic disease largely excluded. Treatment is two sequential percutaneous hepatic perfusions delivering high-dose melphalan with extracorporeal hemofiltration 6–8 weeks apart, followed by up to 1 year of weekly tebentafusp (a gp100 peptide–HLA-directed TCR/anti-CD3 bispecific that redirects T cells to gp100-expressing melanoma cells), with additional PHP allowed on progression as standard of care.

ClinicalTrials.gov ID: NCT07276386